• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reversal of myelofibrosis by hydroxyurea.

作者信息

Löfvenberg E, Wahlin A, Roos G, Ost A

机构信息

Department of Medicine, University of Umeå, Sweden.

出版信息

Eur J Haematol. 1990 Jan;44(1):33-8. doi: 10.1111/j.1600-0609.1990.tb00344.x.

DOI:10.1111/j.1600-0609.1990.tb00344.x
PMID:2307218
Abstract

Bone marrow morphology in 39 symptomatic patients with myeloproliferative disorders (polycythaemia vera 15, essential thrombocythaemia 14, idiopathic myelofibrosis 9, myeloproliferative syndrome 1) and elevated platelet counts was studied before and after a median of 18 months of continuous treatment with hydroxyurea. We found a significant reduction of bone marrow fibrosis, believed to be mediated by suppression of thrombopoiesis by hydroxyurea.

摘要

相似文献

1
Reversal of myelofibrosis by hydroxyurea.
Eur J Haematol. 1990 Jan;44(1):33-8. doi: 10.1111/j.1600-0609.1990.tb00344.x.
2
Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.羟基脲治疗真性红细胞增多症、原发性血小板增多症和骨髓纤维化
Eur J Haematol. 1988 Oct;41(4):375-81. doi: 10.1111/j.1600-0609.1988.tb00212.x.
3
Polycythaemia vera: bone marrow histopathology under treatment with interferon, hydroxyurea and busulphan.真性红细胞增多症：干扰素、羟基脲和白消安治疗下的骨髓组织病理学
Eur J Haematol. 2000 Jan;64(1):32-41. doi: 10.1034/j.1600-0609.2000.90031.x.
4
Polycythaemia after myeloid metaplasia with fibrosis: an unusual sequence.
Haematologica. 1992 Sep-Oct;77(5):433-4.
5
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.真性红细胞增多症、原发性血小板增多症以及原发性骨髓纤维化伴或不伴JAK2 V617F突变时的巨核细胞形态及临床参数
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.
6
Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis.慢性特发性骨髓纤维化中与治疗相关的骨髓变化。
Histol Histopathol. 2004 Jan;19(1):239-50. doi: 10.14670/HH-19.239.
7
The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.原发性血小板增多症、真性红细胞增多症和慢性特发性骨髓纤维化中骨髓纤维化的发生率：对连续骨髓活检的回顾性评估
Acta Haematol. 2005;113(2):137-43. doi: 10.1159/000083452.
8
Cutaneous involvement by post-polycythemia vera myelofibrosis.真性红细胞增多症后骨髓纤维化的皮肤受累情况。
Am J Hematol. 2014 Apr;89(4):448. doi: 10.1002/ajh.23539. Epub 2013 Jul 30.
9
Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis.慢性特发性骨髓纤维化患者接受减瘤治疗后的骨髓组织病理学
Histopathology. 2003 Nov;43(5):470-9. doi: 10.1046/j.1365-2559.2003.01732.x.
10
A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF).一项评估 panobinostat（LBH589）在原发性骨髓纤维化（PMF）和真性红细胞增多症/原发性血小板增多症后骨髓纤维化（post-PV/ET MF）患者中的 I 期研究。
Br J Haematol. 2013 Apr;161(1):68-75. doi: 10.1111/bjh.12220. Epub 2013 Jan 21.

引用本文的文献

1
The sympathomimetic agonist mirabegron did not lower -V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14.拟交感神经激动剂米拉贝隆并未降低-V617F 等位基因负担，但恢复了骨髓增殖性肿瘤患者的巢蛋白阳性细胞并减少了网状纤维纤维化：SAKK 33/14 期研究结果。
Haematologica. 2019 Apr;104(4):710-716. doi: 10.3324/haematol.2018.200014. Epub 2018 Nov 8.
2
Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.当前对骨髓增殖性肿瘤的分子发病机制和治疗的展望。
Mol Diagn Ther. 2012 Oct;16(5):269-83. doi: 10.1007/s40291-012-0006-3.
3
How I treat splenomegaly in myelofibrosis.
我如何治疗骨髓纤维化所致的脾肿大。
Blood Cancer J. 2011 Oct;1(10):e37. doi: 10.1038/bcj.2011.36. Epub 2011 Oct 7.
4
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.伊马替尼与酪氨酸激酶抑制在BCR-ABL阴性骨髓增殖性疾病治疗中的应用
Biologics. 2007 Jun;1(2):129-38.
5
Bone marrow hyaluronan and reticulin in patients with malignant disorders.恶性疾病患者骨髓中的透明质酸和网状纤维。
Med Oncol. 2010 Sep;27(3):618-23. doi: 10.1007/s12032-009-9257-1. Epub 2009 Jun 23.
6
Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.原发性血小板增多症和真性红细胞增多症患者在使用阿那格雷治疗期间骨髓纤维化的进展。
Med Oncol. 2007;24(1):63-70. doi: 10.1007/BF02685904.
7
Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia.沙利度胺对骨髓化生的骨髓纤维化患者的临床疗效可忽略不计。
Med Oncol. 2002;19(2):79-86. doi: 10.1385/mo:19:2:79.
8
Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia. French INSERM Research Network on Myelofibrosis with Myeloid Metaplasia.骨髓纤维化：伴有髓外化生的骨髓纤维化的发病机制。法国国家健康与医学研究院骨髓纤维化伴髓外化生研究网络。
Springer Semin Immunopathol. 1999;21(4):491-508. doi: 10.1007/BF00870307.
9
Primary thrombocythemia: diagnosis, clinical manifestations and management.
Ann Hematol. 1993 Aug;67(2):57-62. doi: 10.1007/BF01788127.
10
The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML--a comparative morphometric study on sequential trephine biopsies.干扰素与白消安疗法对慢性粒细胞白血病中网硬蛋白染色测定的纤维化的影响——一项对连续骨髓活检的比较形态计量学研究
Ann Hematol. 1995 Mar;70(3):121-8. doi: 10.1007/BF01682031.